SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Glimelius Bengt)) srt2:(2015-2019)
 

Search: (WFRF:(Glimelius Bengt)) srt2:(2015-2019) > (2016) > Eight Cycles of ABV...

  • Carde, PatriceGustave Roussy Canc Campus, F-94805 Villejuif, France. (author)

Eight Cycles of ABVD Versus Four Cycles of BEACOPP(escalated) Plus Four Cycles of BEACOPP(baseline) in Stage III to IV, International Prognostic Score >= 3, High-Risk Hodgkin Lymphoma : First Results of the Phase III EORTC 20012 Intergroup Trial

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-298840
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-298840URI
  • https://doi.org/10.1200/JCO.2015.64.5648DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Purpose To compare patients with high-risk stage III to IV Hodgkin lymphoma (HL) in the phase III European Organisation for Research and Treatment of Cancer 20012 Intergroup trial (Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma) who were randomly assigned to either doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP). Patients and Methods Patients with clinical stage III or IV HL, International Prognostic Score of 3 or higher, and age 60 years or younger received ABVD for eight cycles (ABVD(8)) or escalated-dose BEACOPP (BEACOPP(escalated)) for four cycles followed by baseline BEACOPP (BEACOPP(baseline)) for four cycles (BEACOPP(4+4)) without radiotherapy. Primary end points were event-free survival (EFS), treatment discontinuation, no complete response (CR) or unconfirmed complete response (CRu) after eight cycles, progression, relapse, or death. Secondary end points were CR rate, overall survival (OS), quality of life, secondary malignancies, and disease-free survival in CR/CRu patients. Results Between 2002 and 2010, 549 patients were randomly assigned to ABVD(8) (n = 275) or BEACOPP(4+4) (n = 274). Other characteristics included median age, 35 years; male, 75%; stage IV, 74%; "B" symptoms, 81%; and International Prognostic Score >= 4, 59%. WHO performance status was 0 (34%), 1 (48%), or 2 (17%). Median follow-upwas 3.6 years. CR/CRu was 82.5% in both arms. At 4 years, EFS was 63.7% for ABVD(8) versus 69.3% for BEACOPP(4+4) (hazard ratio [HR], 0.86; 95% CI, 0.64 to 1.15; P = .312); disease-free survival was 85.8% versus 91.0% (HR, 0.59; 95% CI, 0.33 to 1.06; P = .076), and OS was 86.7% versus 90.3% (HR, 0.71; 95% CI, 0.42 to 1.21; P = .208). Death as a result of toxicity occurred in six and five patients, early discontinuation (before cycle 5) in 12 and 26 patients, treatment crossovers in five and 10 patients, and secondary malignancies in eight and 10 patients in the ABVD(8) and BEACOPP(4+4) arms, respectively. Conclusion ABVD(8) and BEACOPP(4+4) resulted in similar EFS and OS in patients with high-risk advanced-stage HL. Because BEACOPP(4+4) did not demonstrate a favorable effectiveness or toxicity ratio compared with ABVD(8), treatment burden, immediate and late toxicities, and associated costs must be considered before selecting one of these regimens on which to build future treatment strategies.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Karrasch, MatthiasEuropean Org Res & Treatment, Canc Headquarters, Brussels, Belgium. (author)
  • Fortpied, CatherineEuropean Org Res & Treatment, Canc Headquarters, Brussels, Belgium. (author)
  • Brice, PaulineHop St Louis, Paris, France. (author)
  • Khaled, HusseinNatl Canc Inst, Cairo, Egypt. (author)
  • Casasnovas, OlivierCtr Hosp Univ CHU Dijon, Dijon, France. (author)
  • Caillot, DenisCtr Hosp Univ CHU Dijon, Dijon, France. (author)
  • Gaillard, IsabelleCHU Henri Mondor, F-94010 Creteil, France. (author)
  • Bologna, SergeCtr Hosp Reg Univ CHR Nancy, Nancy, France. (author)
  • Ferme, ChristopheGustave Roussy Canc Campus, F-94805 Villejuif, France. (author)
  • Lugtenburg, Pieternella JohannaErasmus MC, Inst Canc, Rotterdam, Netherlands. (author)
  • Morschhauser, FrankCHR Lille, Lille, France. (author)
  • Aurer, IgorUniv Hosp Ctr Zagreb, Zagreb, Croatia. (author)
  • Coiffier, BertrandCHU Lyon, Lyon, France. (author)
  • Meyer, RalphJuravinski Canc Ctr, Hamilton, ON, Canada. (author)
  • Seftel, MatthewCanc Care Manitoba, Winnipeg, MB, Canada. (author)
  • Wolf, MaxPeter MacCallum Canc Inst, East Melbourne, Vic, Australia. (author)
  • Glimelius, BengtUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)bengglim (author)
  • Sureda, AnnaHosp Santa Creu & Sant Pau, Barcelona, Spain. (author)
  • Mounier, NicolasHop Archet, Nice, France. (author)
  • Gustave Roussy Canc Campus, F-94805 Villejuif, France.European Org Res & Treatment, Canc Headquarters, Brussels, Belgium. (creator_code:org_t)

Related titles

  • In:Journal of Clinical Oncology34:17, s. 2028-+0732-183X1527-7755

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view